High-throughput IgG quantitation platform for clone screening during drug discovery and development

Overview

Biologic drugs are the largest and fastest growing segment of the pharmaceutical industry with sales of $350bn and an annual growth of 8%. Every manufacturing process for potential biologics begins with cell line development, whether it's for clinical trials or a market launch. Monoclonal antibodies (mAbs) have established themselves as the leading biopharmaceutical therapeutic modality. The establishment of robust manufacturing platforms is key for antibody drug discovery efforts to seamlessly translate into clinical and commercial successes. The accurate and reliable measurement of mAbs (e.g., IgG titer) is essential in the development and subsequent manufacturing to ensure optimal cell culture performance to produce all biologics. The ability to reliably monitor protein titer in real time throughout a bioprocess allows operators to rapidly adjust the process conditions for maximum protein output while minimizing process time. Quick access to titer data also enables earlier decisions regarding preparation of downstream processes, further reducing the production timeline.

Here, we provide an overview of a fully optimized rapid, robust, and accurate IgG titer platform combining Valitacell’s Valita®TITER IgG quantitation assay with a suite of Molecular Devices fluorescence polarization (FP) configured microplate readers. The Valita®TITER assay range measures IgG concentrations from 2.5 to 100 mg/L, or 100 to 2000 mg/L, with a simple add-and-read protocol. Valita®TITER plates come precoated with a fluorescently-labeled target-specific probe that the user reconstitutes prior to IgG test sample addition. The assay is performed in less than 15 minutes and can be incorporated into the bioprocess workflow in a 96- or 384-well plate format. The assays are high throughput and can be fully automated. Analyses can be carried out in crude cell culture media containing up to 10 x 10^6 cells/mL, with a low sample volume and limited test sample pre-preparation. Assay detection can be performed using fluorescence polarization on Molecular Devices microplate readers: SpectraMax i3x, iD5, Paradigm, and MS Multi-Mode Microplate Readers. (The i3x and Paradigm readers require the Fluorescence Polarization Detection Cartridge.)

Valita TITER Assay Principle

Valita®TITER and Valita®TITER Plus are rapid, high-throughput assays quantifying IgG-Fc interactions with a fluorescently labeled derivative of protein G using FP for detection. FP effectively analyzes changes in the size of molecules Figure 1. ‘Fixed’ fluorophores are excited by polarized light and preferentially emit light in the same plane of polarization. The rotation of the molecules between absorption and emission of the photon results in ‘twisting’ the polarization of the light. Small molecules tumble faster in solution than larger molecules. Hence, the change in molecule size upon the binding of a fluorescently labeled Fc-specific probe can be detected using the degree of light depolarization. When the fluorescently labeled IgG-binding peptide is unbound, it tumbles rapidly, depolarizing the light more than when bound to an IgG (which is ~20 times larger). The detection of FP involves excitation of the solution with plane polarized light and subsequent measurement of emitted light intensity in both the parallel (polarized portion) and perpendicular (depolarized portion) planes to the exciting light. The FP is expressed as a normalized difference of the two intensities, typically expressed in millipolarization units (mP).

**Figure 1.** The assay applies fluorescence polarization to quantify Fc-containing IgG. Small, unbound molecules rotate rapidly in solution (top), while large, bound molecules rotate slowly (bottom).

Method

- A serial dilution of IgG standards was performed, using XP Media-L-glutamine as the diluant, to concentrations from 2.5–100 mg/L (Valita®TITER) or 100–2000 mg/L (Valita®TITER Plus).
- 60 µL of medium was pipetted into each well of the Valita®TITER or Valita®TITER Plus plate to reconstitute the probe.
- 60 µL of prepared standards were then added to the appropriate wells.
- Well contents were mixed by gently pipetting up and down three times (see Figure 2 for assay workflow overview).
- Assay plates were incubated in the dark for five minutes (Valita®TITER), or 15 minutes (Valita®TITER Plus) at room temperature prior to measurement on a suite of Molecular Devices microplate readers, using the identified fully optimized methods outlined in Table 2 (Valita®TITER) and Table 3 (Valita®TITER Plus).

Results

An investigation was carried out in order to identify the optimal parameters for using Valitacell’s Valita®TITER assays on Molecular Devices suite of multi-mode microplate readers in order to provide a cost-effective, high-throughput IgG quantitation platform for use in high-throughput drug discovery and development. IgG standard curves were prepared and analyzed using a simple add-and-read method, with no sample or plate pre-preparation or wash steps required, and an easy workflow. Superior results were obtained using built-in monochromator optics for excitation at 485 nm, and a 535 nm FP filter set for emission using the SpectraMax i3x reader. IgG standards from 2.5 mg/L to 100 mg/L (Valita®TITER) or 100 mg/L to 2000 mg/L (Valita®TITER Plus) were detected with a high degree of linearity (R^2 = 0.99) across the entire range (Figure 3). Comparable data for Valita®TITER (Table 4) and Valita®TITER Plus assay (Table 5) were obtained with the SpectraMax i3x, Paradigm, and MS readers. A preconfigured protocol in SoftMax® Pro Software automated the mP calculations and curve plotting.

**Figure 2.** Each well of the assay plate is pre-coated with a fluorescently labeled Fc-specific probe (1). An IgG sample binds to the probe (2). Binding is measured via fluorescence polarization (3).

**Table 1.** Overview of key features of Valita®TITER versus competitors.

**Table 2.** Optimal instrument settings for Valita®TITER assay Fluorescence Polarization Measurement on Molecular Devices microplate readers. SpectraMax i3x and Paradigm readers require the FP-FLUO detection cartridge. Settings not required by a reader are indicated by ‘—’.

**Table 3.** Optimal instrument settings for Valita®TITER Plus assay Fluorescence Polarization Measurement on Molecular Devices microplate readers. SpectraMax i3x and Paradigm readers require the FP-FLUO detection cartridge. Settings not required by a reader are indicated by ‘—’.

**Table 4.** Standard delta mP, average standard deviation (SDmP) and %CV (n = 4) for Valita®TITER standards read on Molecular Devices readers.

**Table 5.** Standard delta mP, average standard deviation (SDmP) and %CV (n = 4) for Valita®TITER Plus standards read on Molecular Devices readers.

Conclusion

- The accurate and reliable measurement of mAb IgG titer is essential in the development and subsequent manufacture to ensure optimal cell culture performance.
- The Valita®TITER assay range combined with Molecular Devices suite of plate readers provides a rapid, high-throughput, and cost-effective solution for IgG quantification throughout drug discovery and development.
- Valita®TITER is robust to cellular contamination and facilitates ‘straight from reactor measurement’ across a wide functional range.
- This 96-well assay has been fully validated on the SpectraMax iD5 reader and other Molecular Devices microplate readers with FP detection to ensure reliable results.
- SoftMax Pro Software minimizes setup time for detection and automates standard curve fitting and sample quantitation.